Drugs News and Research

RSS

Scripps Research receives $2.2M NIH grant to develop novel therapeutics for substance abuse

The Scripps Research Institute has been awarded a $2.2 million grant from the National Institutes of Health (NIH) to develop novel therapeutics for the treatment of addiction to multiple substances in a national effort with the University of Kansas.

10 Jun 2011

Study identifies sharp rise in Parkinson's prevalence in Israel from 2000 to 2007

In a new study published today in the inaugural issue of the Journal of Parkinson's Disease, Israeli researchers report that by tracking pharmacy purchases of anti-Parkinson drugs they could estimate the number of Parkinson's disease (PD) cases in a large population.

10 Jun 2011

LGL to host third annual pharmacogenetic conference on 8-9th November 2011

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, is pleased to announce that its third annual pharmacogenetic conference will feature top-level presentations from players in all parts of the healthcare chain.

10 Jun 2011

NIH awards $1.9M grant to Scripps Research scientist for malaria study

A scientist from The Scripps Research Institute has won a four-year, $1.9 million grant from the National Institutes of Health to better understand the parasite that causes malaria, laying the groundwork to develop better drugs to combat the widespread and deadly disease.

10 Jun 2011

FDA draft guidance outlines roadmap for discussion on nanotechnology in regulated products

The U.S. Food and Drug Administration today released draft guidance to provide regulated industries with greater certainty about the use of nanotechnology, which generally involves materials made up of particles that are at least one billionth of a meter in size. The guidance outlines the agency's view on whether regulated products contain nanomaterials or involve the application of nanotechnology.

10 Jun 2011

FDA grants Fast Track Designation for Emergent BioSolutions' NuThrax vaccine

Emergent BioSolutions Inc. announced today that its investigational anthrax vaccine, NuThrax, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA).

10 Jun 2011

FDA CDER, ChanTest enter research collaboration agreement

ChanTest Corporation has entered into a research collaboration with the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER).

10 Jun 2011

Drugs for enlarged prostate raise cancer risk

According to health officials, this Thursday, a class of drugs meant to improve symptoms of an enlarged prostate gland may actually increase the chance of getting a more serious form of prostate cancer. However they also said the drugs' benefits outweigh the risks.

9 Jun 2011

Smoking keeps weight off: Study finds out how

The researchers have found that nicotine activates a pathway in the brain that suppresses appetite. The study was published in the journal Science. The authors believe this discovery should lead to better diet drugs.

9 Jun 2011

Global initiative to prevent HIV in babies

World leaders met to decide on the launch of a global plan with the goal of ensuring that every baby is born HIV-free by 2015 and that their mothers with the HIV virus live to raise them.

9 Jun 2011

Being a young man is risky business for health

The Royal Australian College of General Practitioners (RACGP) is highlighting that young Australian men have higher rates of risky behaviours than young women and that this can put their health at immediate and long term risk. This warning comes as International Men’s Health Week takes place from 13 – 19 June 2011.

9 Jun 2011

European Bioinformatics Institute drives genomics research with GÉANT

The European Molecular Biology Laboratory’s European Bioinformatics Institute (EMBL-EBI), which hosts the world’s largest public collection of molecular biology databases, is using the pan-European GÉANT research network and JANET, the UK research network, to help biologists share vital data across the globe.

9 Jun 2011

Respira introduces breakthrough Dry Powder Inhaler

Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, introduces the company's Dry Powder Inhaler (DPI) as a breakthrough solution for the pharmaceutical industry. Based on proprietary drug engine technology (DET), Respira Therapeutics' DPI significantly improves therapeutic performance and enables addressing the unmet medical needs of patients with severe respiratory diseases.

9 Jun 2011

Synaptophysin controls replacement of vesicles

A University of Wisconsin-Madison research team has solved a 25-year mystery that may lead to better treatments for people with learning deficits and mental retardation.

9 Jun 2011

Celerion earns ANVISA certification to conduct clinical research operations in Belfast, Lincoln

Celerion, the premier provider of innovative early stage drug development solutions, is pleased to announce that its clinical research operations in Belfast, Northern Ireland UK, and its clinical research and bioanalytical services operations in Lincoln, Nebraska USA, have been certified by the Brazilian National Health Surveillance Agency.

9 Jun 2011

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck, known as MSD outside the United States and Canada, today announced changes to the prescribing information in the United States for the highest dose of simvastatin, 80 mg, and the use of simvastatin with certain other medicines.

9 Jun 2011

U.S. FDA announces safety label changes for cholesterol-lowering medication, simvastatin

The U.S. Food and Drug Administration today is announcing safety label changes for the cholesterol-lowering medication simvastatin because the highest approved dose--80 milligram (mg)--has been associated with an elevated risk of muscle injury or myopathy, particularly during the first 12 months of use.

9 Jun 2011

TD2, Imaging Endpoints team up to enable rapid development of anti-cancer drugs

TGen Drug Development (TD2) and Imaging Endpoints have teamed up to enable the rapid development of anti-cancer drugs and deliver them faster to patients in need, the companies announced today.

9 Jun 2011

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Avila Therapeutics, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that it has achieved a significant goal in its alliance with Clovis Oncology, Inc.

9 Jun 2011

IPS examines negotiations over intellectual property laws affecting generic AIDS drugs

Inter Press Service examines how "moves by developed nations such as the United States to tighten intellectual property laws are threatening to limit production and distribution of generic drugs, which experts say have been and will remain key in the prevention and treatment of HIV/AIDS and currently account for 80 percent of HIV/AIDS treatment."

9 Jun 2011

Drugs News and Research

Scripps Research receives $2.2M NIH grant to develop novel therapeutics for substance abuse

Study identifies sharp rise in Parkinson's prevalence in Israel from 2000 to 2007

LGL to host third annual pharmacogenetic conference on 8-9th November 2011

NIH awards $1.9M grant to Scripps Research scientist for malaria study

FDA draft guidance outlines roadmap for discussion on nanotechnology in regulated products

FDA grants Fast Track Designation for Emergent BioSolutions' NuThrax vaccine

FDA CDER, ChanTest enter research collaboration agreement

Drugs for enlarged prostate raise cancer risk

Smoking keeps weight off: Study finds out how

Global initiative to prevent HIV in babies

Being a young man is risky business for health

European Bioinformatics Institute drives genomics research with GÉANT

Respira introduces breakthrough Dry Powder Inhaler

Synaptophysin controls replacement of vesicles

Celerion earns ANVISA certification to conduct clinical research operations in Belfast, Lincoln

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

U.S. FDA announces safety label changes for cholesterol-lowering medication, simvastatin

TD2, Imaging Endpoints team up to enable rapid development of anti-cancer drugs

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

IPS examines negotiations over intellectual property laws affecting generic AIDS drugs

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News